Results 271 to 280 of about 7,977,848 (398)

Financing for health: where there's a will…

The Lancet Global Health, 2016
openaire   +3 more sources

TRPM8 levels determine tumor vulnerability to channel agonists

Molecular Oncology, EarlyView.
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo, Francesco Giuseppe Carbone, Kristi Buzo, Nicole Annesi, Sacha Genovesi, Annalisa Lorenzato, Karen Widmann, Michela Libergoli, Elisa Marmocchi, Giovanni Bertalot, Alberto Brolese, Mauro Giulio Papotti, Luca Molinaro, Orazio Caffo, Mattia Barbareschi, Alberto Bardelli, Alessandro Romanel, Sabrina Arena, Andrea Lunardi   +18 more
wiley   +1 more source

Tobacco control in the Sustainable Development Goals: a precarious inclusion?

The Lancet Public Health, 2017
Roy Small, Natalia Linou, Douglas Webb, Mandeep Dhaliwal   +3 more
doaj   +1 more source

Leveraging health financing, digital health and self-care approaches to strengthen maternal health journeys in India: perspectives from Assam. [PDF]

Front Glob Womens Health
Ramesh S, Warren CE, Bellows B, Dwivedi H, Gupta H, Munjral A, Rawat S, Tresner-Kirsch D, Nagpal J.   +8 more
europepmc   +1 more source

Iranian health financing system challenges to promote health outcomes: Qualitative study. [PDF]

J Educ Health Promot, 2023
Jabbari A, Zakeri A, Saghafi F, Hadian M.   +3 more
europepmc   +1 more source

health care financing and health systems planning for afghanistan 1992

, 2000
Maysam Hussain, Gilles Manuel, I F T I Khar Ali, Aric -Ms Dupree, Avicen -Ms Mounier, Abdul Mehraban, Irc -Mr William, Housaini Tawfik, M. Michael, Scf Ahart, Allandad Scna -, Zalmai Sswa -, Anwar Khan   +12 more
openalex   +1 more source

The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

Molecular Oncology, EarlyView.
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu   +10 more
wiley   +1 more source

Health outcome convergence and the roles of public health financing and governance in Africa. [PDF]

PLoS One
Ndzignat Mouteyica AE, Ngepah NN.
europepmc   +1 more source

Quality or financing: what drives design of the health care system? [PDF]

, 2003
V. McLoughlin
openalex   +1 more source

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

Molecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow   +10 more
wiley   +1 more source